1 DRUG-RESISTANT TUBERCULOSIS CASE-FINDING STRATEGIES: A SCOPING REVIEW

2 PROTOCOL

- 3 Susanna S van Wyk
- 4 Centre for Evidence Based Health Care, Division of Epidemiology and Biostatistics,
- 5 Department of Global Health, Stellenbosch University, Cape Town, South Africa
- 6 <u>susanvanwyk@sun.ac.za</u>
- 7 Marriott Nliwasa
- 8 Helse Nord Tuberculosis Initiative, Kamuzu University of Health Sciences, Blantyre,
- 9 Malawi
- 10 <u>mnliwasa@gmail.com</u>
- 11 James A Seddon
- 12 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of
- 13 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- 14 Department of Infectious Diseases, Imperial College London, London, United
- 15 Kingdom
- 16 james.seddon@imperial.ac.uk
- 17 Graeme Hoddinott
- 18 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of
- 19 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- 20 graemeh@sun.ac.za
- 21 Lario Viljoen
- 22 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of
- 23 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- 24 lario@sun.ac.za
- 25 Emmanuel Nepolo

- 26 Department of Human, Biological and Translational Medical Science, School of
- 27 Medicine, University of Namibia, Windhoek, Namibia
- 28 <u>enepolo@unam.na</u>
- 29 Gunar Günther
- 30 Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University
- 31 of Bern, Bern, Switzerland
- 32 Department of Human, Biological & Translational Medical Science, School of
- 33 Medicine, University of Namibia, Windhoek, Namibia
- 34 gunarguenther@gmx.de
- 35 Nunurai Ruswa
- 36 Clinical and Programmatic Coordinator for Drug Resistant Tuberculosis, Ministry of
- 37 Health and Social Services, Windhoek, Namibia
- 38 <u>ncruswa@gmail.com</u>
- 39 Hsien-Ho Lin
- 40 Institute of Epidemiology and Preventive Medicine, National Taiwan University,
- 41 Taiwan
- 42 <u>hsienho@g.ntu.edu.tw</u>
- 43 Stefan Niemann
- 44 Molecular and Experimental Mycobacteriology Group and National Reference
- 45 Center for Mycobacteria, Forschungszentrum Borstel, Germany
- 46 <u>stniemann@yahoo.de</u>
- 47 Neel Gandhi
- 48 Departments of Epidemiology and Global Health, Rollins School of Public Health,
- 49 Emory University, Atlanta, USA
- 50 <u>neel.r.gandhi@emory.edu</u>
- 51 Sarita Shah

- 52 Departments of Epidemiology and Global Health, Rollins School of Public Health,
- 53 Emory University, Atlanta, USA
- 54 sarita.shah@emory.edu
- 55 Mareli Claassens (Corresponding author)
- 56 Department of Human, Biological and Translational Medical Science, School of
- 57 Medicine, University of Namibia, Windhoek, Namibia
- 58 Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of
- 59 Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- 60 <u>mcla@sun.ac.za</u>
- 61 Mailing address:
- 62 University of Namibia, Private Bag 13301, Windhoek, Namibia

63 ABSTRACT

64 Background

- 55 Transmission of drug-resistant tuberculosis (TB) is ongoing, and many households face
- 66 catastrophic costs when a member is diagnosed and treated for drug-resistant TB. Finding
- 67 individuals with drug-resistant TB and initiating treatment as early as possible is important to
- 68 improve patient clinical outcomes and to break the chain of transmission to help control the
- 69 pandemic.
- 70 To our knowledge systematic reviews assessing effectiveness, cost-effectiveness,
- 71 acceptability and feasibility of different drug-resistant TB case-finding strategies to inform
- research, policy and practice, have not been conducted and it is unknown whether enough
- 73 research exists to conduct such reviews. It is also unknown whether case-finding strategies
- 74 are similar for drug-resistant TB and drug-susceptible TB and whether we can draw on
- 75 findings from drug-susceptible reviews to inform decisions on drug-resistant TB case-finding
- 76 strategies.

77 Methods

78	The question for ou	r review is: what literature	is available on drug-resistant T	B case finding
----	---------------------	------------------------------	----------------------------------	----------------

- 79 and which case-finding strategies are described? We will look at studies that have sought to
- 80 improve drug-resistant TB case detection. We will search the academic databases of
- 81 CENTRAL, MEDLINE and EMBASE using no language or date restrictions. We will apply broad
- 82 criteria for screening titles, abstracts and full text articles. A data extraction form will be
- 83 developed in excel and applied to all primary research reports to collect standard
- 84 information on each study. We will provide a narrative report with supporting figures and/or
- tables to summarize the data. A systems-based logic model, developed from a synthesis of
- 86 drug-susceptible TB case-finding strategies, will be used as a framework to describe different
- 87 strategies, resulting pathways and enhancements of pathways.

88 Discussion

- 89 This scoping review will chart existing literature on drug-resistant TB case finding and
- 90 identify priority question(s) for a systematic review. It will also describe drug-resistant TB
- 91 case-finding strategies and how they fit into a model of drug-susceptible TB case-finding
- 92 pathways. The review will guide further research to inform decisions on drug-resistant TB
- 93 case finding policy and practice.

94 KEYWORDS

- 95 Tuberculosis, drug-resistant tuberculosis, drug-resistant tuberculosis case finding, drug-
- 96 resistant tuberculosis case detection, drug-resistant tuberculosis screening

97 BACKGROUND

- 98 With the emergence of Mycobaterium tuberculosis (M. tb) strains resistant to first line anti-
- 99 tuberculosis drugs, strategies to control tuberculosis (TB) became even more challenging.¹ It
- 100 is estimated that almost half a million people developed rifampicin-resistant (RR) TB, of
- 101 which 78% had multidrug-resistant TB (MDR-TB) in 2019.² Although drug-resistant TB is not

102	as prevalent as drug-susceptible TB, it is more difficult to diagnose, treatment is longer and
103	more toxic, outcomes are worse and costs are higher. Sixty-seven to 100% of people with
104	drug-resistant TB in their households face catastrophic costs (total costs equivalent to >20%
105	of annual household income). ²
106	Finding individuals with drug-resistant TB and initiating treatment as early as possible is
107	important to improve patient clinical outcomes and to break the chain of transmission to
108	help control the pandemic. But despite new diagnostic technologies, only 38% of the
109	estimated number of people who developed drug-resistant TB initiated treatment in 2019. ^{2,3}
110	TB can be detected following the patient presenting passively to health services or following
111	one of several different screening pathways depending on the case-finding strategy of a TB
112	programme. ⁴ Pathways can also be enhanced via several activities such as health promotion
113	in the community, improved access to TB diagnostic services or training of health workers to
114	identify presumptive TB at general health services. Multiple activities often result in complex
115	interventions and heterogeneous trials which are difficult to meta-analyse in systematic
116	reviews. ^{5,6}
117	To our knowledge systematic reviews assessing effectiveness, cost-effectiveness,
118	acceptability and feasibility of different drug-resistant TB case-finding strategies to inform
119	research, policy and practice, have not been conducted and it is unknown whether enough
120	research exists to conduct such reviews. It is also unknown whether case-finding strategies
121	are similar for drug-resistant TB and drug-susceptible TB and whether we can draw on
122	findings from drug-susceptible reviews to inform decisions on drug-resistant TB case-finding
123	strategies.
124	We will therefore conduct a scoping review to chart existing literature on drug-resistant TB
125	case finding and identify priority question(s) for a systematic review. ^{7,8} We will also describe
126	existing strategies and how they fit into a model of drug-susceptible TB case-finding
127	pathways.

5

128 METHODS

- 129 The Arksey and O'Malley framework^{9,10}, the Joanna Briggs Institute scoping review
- 130 methodology⁸ and the PRISMA extension for scoping reviews (PRISMA-ScR)¹¹ will guide
- 131 methods for this scoping review.

132 **Defining the research question**

- 133 The question for our review is: what literature is available on drug-resistant TB case finding
- and which case-finding strategies are described? We will look at studies that have sought to
- 135 improve drug-resistant TB case detection.

136 Identifying relevant studies

- 137 We will use the following eligibility criteria:
- 138 Inclusion criteria
- 139 Participants
- 140 Participants can be any age or gender. They can be people receiving an intervention or
- 141 providers of an intervention.

142 • Concept

- 143 Intervention strategies aiming to improve or enhance participants' pathway(s) to drug-
- 144 resistant TB case detection specifically. Intervention strategies aiming to improve TB
- 145 case finding in general and only report on the yield of drug-resistant TB cases will be
- 146 excluded.
- 147 Context
- 148 Studies conducted at primary care, secondary care, tertiary care or community settings.
- 149 We will exclude studies that are purely laboratory based, but will include studies where
- screening of sputum samples is part of an intervention to improve drug-resistant TB case
- 151 finding.
- 152 Study designs

153	Systematic reviews, excluding narrative reviews. Primary studies irrespective of study
154	design. Qualitative studies, where the experiences of individuals who receive the
155	intervention or those who provide the intervention are investigated. We will include
156	studies of diagnostic test accuracy if the study describes a drug-resistant TB screening
157	strategy and we will include trials comparing different screening or diagnostic tools
158	within case-finding interventions. We will exclude prevalence surveys, except if the
159	survey includes an intervention strategy to find drug-resistant TB cases specifically. We
160	will exclude editorials, opinion articles, meeting summaries and guidelines.
161	We will search the academic databases of Medline (PubMed), Embase (Ovid), The Cochrane
162	Library, Africa-Wide Information (EBSCOhost), CINAHL (EBSCOhost), Epistemonikos and
163	PROSPERO using no language or date restrictions. Reference lists of included studies will be
164	searched.
165	The preliminary search string will include combinations of the following three domains:
166	 terms related to "tuberculosis"
167	 terms related to "drug resistance"
168	• terms related to "case finding", "case detection", "screening", "contact investigation"
169	and "contact tracing"
170	Appropriate MesH terms will be added to the different databases. The search strategy will
171	be piloted and refined in consultation with an information specialist. We will also contact
172	experts working in the field to collect information about ongoing primary research or
173	relevant research missed by the electronic search.
174	Study selection
175	We will use Rayyan systematic review software ¹² to screen titles, abstracts and full text
176	articles. Four reviewers (SvW, MN, LV and MC) will screen abstracts in duplicate for
177	inclusion. They will resolve conflicts via discussion and meet at the beginning and midpoint
178	of abstract screening to discuss challenges and possible refinement of the search strategy.

7

- 179 Three reviewers (SvW, LV and MN) will then screen full text articles for inclusion.
- 180 Disagreements will be resolved with a third reviewer (MC) to determine final inclusion.

181 Charting the data

- 182 We will develop a data extraction form in excel. The data extraction form will be applied to
- all primary research reports to collect standard information on each study. Information will
- 184 include:
- 185 Authors, journal, year of publication
- 186 Aim/purpose of the research
- 187 Study design
- Country: income, TB prevalence, human immunodeficiency virus (HIV) prevalence;
- 189 urban/rural setting
- 190 Participants: age, sex, HIV status, other reported risk factors
- 191 Target group and how the group was identified if applicable
- Intervention(s): All components (activities) of the intervention, type(s) of providers and
- 193 screening and diagnostic tools used
- 194 Treatment support, including preventive therapy
- 195 Outcomes assessed
- 196 Five authors (SvW, MN, LV, MC and GH) will extract data, one author per paper. A second
- 197 reviewer (SvW/MC) will check extracted data from each study. The data extraction team and
- 198 other co-authors will meet regularly after each 5-10 studies to determine whether their
- approach is consistent and in line with the research question.

200 Collating, summarizing and reporting the results

- 201 We will provide a narrative report with supporting figures and/or tables to summarize the
- 202 data. Table 1 contains definitions we will use in charting, collating, summarizing and
- 203 reporting our results.

204 Table 1: Definitions

Drug-resistant TB	All types of drug-resistant TB: single drug-resistant TB, multidrug-resistant TB, extensively drug- resistant TB and any other drug-resistant TB reported by the authors.
Systematic screening for	"The systematic identification of people with suspected (presumptive) active TB, in a
active TB	predetermined target group, using tests, examinations or other procedures that can be applied rapidly. Among those screened positive, the diagnosis needs to be established by one or several diagnostic tests and additional clinical assessments, which together have high accuracy." ³
A screening tool	Tests, examinations or other procedures used for systematic screening for active TB. Examples of TB screening tools include a structured symptom-based questionnaire, chest radiography (CXR), or an algorithm. ⁴ Algorithms may include sequential or parallel tests. With sequential tests, only those who screen positive with the initial test receive a second test. With parallel tests, those who screen positive on any of the tests are regarded as screen positives.
A diagnostic tool	Tests, examinations or other procedures used to establish a diagnosis of TB in people identified with presumptive TB. Examples of TB diagnostic tools include a clinical algorithm, sputum smear microscopy, Xpert MTB/RIF or culture. ⁴
TB symptom(s)	Any TB symptom, e.g. cough, fever, night sweats, weight loss or combination of TB symptoms as defined by the study authors.
Care seeking	People seeking care for a perceived health problem.
TB care seeking	People seeking care for TB symptoms specifically.
A risk group	Any group of people in whom the prevalence or incidence of TB is significantly higher than in the general population. Examples of risk groups include a whole population within a geographical area or TB contacts. ³
A clinical risk group	Individuals diagnosed with a specific disease or condition that increases their risk for TB, e.g. people living with HIV (PLHIV).
Presumptive TB	Presumptive TB is identified when a provider identifies a patient with suspected active
	tuberculosis. In the context of screening, a person who screens positive is a presumptive TB case.
Passive case finding	*Some of these definitions overlap and are used inconsistently within the literature. We will
Passive case finding with	therefore use our logic model (Fig 1) to clearly describe pathways rather than labelling them with
an element of systematic	these terms.
screening	
Triage	
Enhanced case finding	
Active case finding	
Contact tracing/ contact	
investigation	
Intensified case finding	
* Van Wyk SS, Medley N, Yo	ung T and Oliver S. Repairing boundaries along path ways to tuberculosis case detection: An
evidence synthesis. Work su	bmitted for publication, June 2021.

205 A systems-based logic model developed from a synthesis of drug-susceptible TB case-finding

strategies (Figure 1) will be used as a framework to describe different strategies and

207 resulting pathways. Enhancements of pathways will also be described and may include

208 enhanced care seeking (e.g. health promotion), improved access to care for those seeking

- 209 care (e.g. mobile clinics), improved access to TB screening (e.g. incentives), improved
- 210 identification of presumptive TB by health workers (e.g. training of health workers,
- 211 incentives) and improved access to TB diagnostic services for individuals identified with
- 212 presumptive TB (e.g. transport, sputum collection in the community, mobile laboratory). For
- screening pathways we will report on target groups and screening and diagnostic tools used.
- 214 Quality appraisal will not be conducted, because this is a scoping review and our interest is
- in the existing evidence base, regardless of study design and quality.

216 **DISCUSSION**

- 217 This scoping review will chart existing literature on drug-resistant TB case finding and
- 218 identify priority question(s) for a systematic review. It will also describe drug-resistant TB
- 219 case-finding strategies and how they fit into a model of drug-susceptible TB case-finding
- 220 pathways.

221 Strengths and limitations

- 222 Our multidisciplinary review team consists of researchers with extensive experience in TB
- 223 related research and the conduct of systematic reviews and qualitative evidence synthesis.
- 224 Their experience would be invaluable in collating and summarizing diverse literature in a
- sensible way. Another strength is the use of a systems-based logic model that was
- developed from a synthesis of drug-susceptible TB case-finding strategies. The model will
- 227 help us to construct meaningful pathway descriptions for possible comparisons in future
- 228 research and to assess whether drug-resistant TB case-finding pathways are similar to drug-
- 229 susceptible pathways.
- 230 One limitation to the review is the diverse and inconsistent use of intervention terminology

within the literature, which may result in missing relevant studies. Although we cannot

overcome this problem in full, we will work with an information specialist to pilot and

- 233 optimize our search strategy and we will discuss potential refinement of our search at
- regular meetings during the screening phase. Poor reporting of intervention strategies may
- also cause misunderstanding and misclassification of interventions. However, we do not
- assess effectiveness as an outcome and therefore bias due to misclassification will be a
- 237 minor issue. Lastly, drug-resistant TB case-finding strategies may not fit into a model
- 238 developed from drug-susceptible strategies. Nevertheless, such a situation will provide an
- 239 opportunity to refine the model for future research.

240 Conclusion

- 241 This scoping review will chart the existing body of literature on drug-resistant TB case-
- 242 finding strategies and will guide further research to inform decisions on drug-resistant TB
- 243 case finding policy and practice.

244 LIST OF ABBREVIATIONS

- 245 TB: tuberculosis
- 246 *M. tb: Mycobaterium tuberculosis (M. tb)*
- 247 **RR:** rifampicin-resistant
- 248 MDR-TB: multidrug-resistant tuberculosis
- 249 **PRISMA-ScR:** PRISMA extension for scoping reviews
- 250 **HIV:** human immunodeficiency virus
- 251 **PLHIV:** people living with human immunodeficiency virus

252 **DECLARATIONS**

- 253 Ethics approval and consent to participate
- 254 Not applicable
- 255 Consent for publication
- 256 Not applicable

257 Availability of data and materials

258 Not applicable

259 Competing interests

260 The authors declare that they have no competing interests

261 Funding

- 262 SvW is supported by the Research, Evidence and Development Initiative (READ-It). READ-It
- 263 (project number 300342-104) is funded by UK aid from the UK government; however, the
- 264 views expressed do not necessarily reflect the UK government's official policies.
- 265 MC is supported jointly by the UK Medical Research Council (MRC) and the UK Foreign,
- 266 Commonwealth & Development Office (FCDO) under the MRC/FCDO Concordat agreement
- and is also part of the EDCTP2 programme supported by the European Union.

268 Authors' contributions

- 269 MC and SvW conceived the study idea. SvW drafted the protocol. All authors read and
- approved the final protocol.

271 Acknowledgements

272 Not applicable

273 **REFERENCES**

- 274 1. Allué-Guardia A, García JI and Torrelles JB. Evolution of Drug-Resistant Mycobacterium
- tuberculosis Strains and Their Adaptation to the Human Lung Environment. Front.
- 276 Microbiol. 2021;12:612675. doi: 10.3389/fmicb.2021.612675.
- 277 2. World Health Organization (WHO). Global tuberculosis report 2020. Geneva: World
- 278 Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
- 279 3. World Health Organization (WHO). Consolidated guidelines on tuberculosis. Module 2:
- 280 Screening -systematic screening for tuberculosis disease. Geneva: World Health
- 281 Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
- 4. World Health Organization (WHO). Systematic screening for active tuberculosis: an
- 283 operational guide. Geneva: World Health Organization; 2015. WHO/HTM/TB/2015.16.
- 284 5. Heuvelings CC, de Vries SG, Greve PF, Visser BJ, Bélard S, Janssen S, et al. Effectiveness of
- 285 interventions for diagnosis and treatment of tuberculosis in hard-to-reach populations in

286 countries of low and medium tuberculosis incidence: a systematic review. Lancet Infe	286	countries of low an	d medium tuber	culosis incidence: a	systematic review.	Lancet Infect
--	-----	---------------------	----------------	----------------------	--------------------	---------------

- 287 Dis. 2017;17:e144-58.
- 288 6. Mhimbira FA, Cuevas LE, Dacombe R, Mkopi A, Sinclair D. Interventions to increase
- 289 tuberculosis case detection at primary healthcare or community level services. Cochrane
- 290 Database Syst Rev. 2017;11(CD011432).
- 291 7. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A and Aromataris E. Systematic
- 292 review or scoping review? Guidance for authors when choosing between a systematic or
- scoping review approach. BMC Medical Research Methodology. 2018;18:143.
- 294 8. Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D and Soares CB. Guidance for
- 295 conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13:141-6.
- 296 9. Arksey H and O'Malley L. Scoping Studies: Towards a Methodlogical Framework. Int. J.
- 297 Social Research Methodology. 2005;8(1):19-32.
- 298 10. Levac D, Colquhoun H and O'Brien KK. Scoping studies: advancing the methodology.
- 299 Implementation Science. 2010;5:69.
- 300 11. Tricco, AC, Lillie, E, Zarin, W, O'Brien, KK, Colquhoun, H, Levac, D, Moher, D, Peters, MD,
- 301 Horsley, T, Weeks, L, Hempel, S et al. PRISMA extension for scoping reviews (PRISMA-
- 302 ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-473.
- 303 12. Mourad Ouzzani, Hossam Hammady, Zbys Fedorowicz, and Ahmed Elmagarmid. Rayyan
- 304 a web and mobile app for systematic reviews. Systematic Reviews (2016) 5:210.

305 FIGURES, TABLES AND ADDITIONAL FILES

306 Figure 1: A systems-based logic model depicting types of services and associated pathways

307 to TB case detection

- 308 The model distinguishes six pathways to TB case detection, namely two care-seeking
- 309 pathways (green and black dashed lines) and four screening pathways (green, blue, orange
- and grey solid lines). People perceiving themselves to have a health problem and access

311	general health services, follow the general care-seeking pathway where a provider can
312	identify presumptive TB on routine assessment, i.e., history taking and clinical examination,
313	of an individual patient (green dashed line). People perceiving themselves to have TB
314	symptoms may also follow the specific TB care-seeking pathway to TB diagnostic services,
315	where all people accessing care are evaluated for possible active TB (black dashed line).
316	People invited to TB services regardless of symptoms follow TB screening pathways and may
317	be identified with presumptive TB even if they do not seek care for TB symptoms. Four
318	screening pathways are distinguished: TB screening offered to all people accessing general
319	health services (green solid line), dedicated TB screening services at a health facility or
320	mobile clinic with open invitation to a whole population or TB contacts (blue solid line), TB
321	screening offered to target group members at home, work or school (orange solid line) and
322	TB screening offered to people living with HIV linked to care (grey solid line). A person who
323	screens positive on the TB screening pathway is identified as a presumptive TB case and
324	should receive confirmation of a diagnosis by accessing TB diagnostic services.

325 Additional file 1

326 The PRISMA-P Checklist

